TNFRSF4 and neoplasm: In addition, we have published studies that described a dramatic age-related decrease in anti-tumor responses mediated by a promising immunotherapy, an OX40 agonist (αOX40) that stimulates the co-stimulatory TNF receptor CD134 [11, 12].